Clinical trials
Phase 3 Brain Injuries trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 4 |
| Unknown status | 3 |
| Withdrawn | 2 |
| Terminated | 2 |
| Suspended | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Washington | 3 |
| BHR Pharma, LLC | 1 |
| Baylor College of Medicine | 1 |
| Daniel Nishijima, MD, MAS | 1 |
| David Wright | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Flowonix Medical | 1 |
| Hospital Sirio-Libanes | 1 |
| Khon Kaen University | 1 |
| Ludwig-Maximilians - University of Munich | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Injuries | 21 |
| Brain Injuries, Traumatic | 11 |
| Wounds and Injuries | 4 |
| Stroke | 3 |
| Cerebral Palsy | 2 |
| Craniocerebral Trauma | 2 |
| Intellectual Disability | 2 |
| Intracranial Hemorrhages | 2 |
| Leukomalacia, Periventricular | 2 |
| Nervous System Diseases | 2 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.